Literature DB >> 17440643

Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension.

Yves Lacourcière1, Luc Poirier, Jean Lefebvre.   

Abstract

OBJECTIVES: The present study investigated whether initiating therapy with a combination of losartan (L) and hydrochlorothiazide (HCTZ) allows for faster blood pressure (BP) control and fewer medications than the usual stepped-care approach in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension.
METHODS: Patients with a mean daytime systolic ambulatory BP (ABP) of 135 mmHg or higher were randomly assigned to receive L 50 mg plus HCTZ 12.5 mg titrated to L 100 mg plus HCTZ 25 mg versus HCTZ 12.5 mg plus atenolol 50 mg. Amlodipine 5 mg was then added, if needed, to achieve a BP goal of less than 130 mmHg. Treatment titration was based on ABP.
RESULTS: Significantly more patients randomly assigned to L/HCTZ (63.5%) than stepped-care (37.5%; P=0.008) achieved the primary end point (daytime systolic BP of less than 130 mmHg). Initial L/HCTZ induced significantly greater decreases in ABP during each 24 h period after six weeks of therapy. Although reductions in systolic and diastolic ABP were not statistically different at the end of the study, ABP reduction was significantly greater (P<0.001) with the L/HCTZ-based regimen. Twice as many patients in the L/HCTZ group achieved the goal ABP with no more than two drugs (30.0% versus 14.7%; P=0.03). Moreover, tolerability was significantly better (P=0.006) in the L/HCTZ group, with a 40.0% incidence of adverse events, versus 65.6% in the stepped-care group.
CONCLUSION: Initiating antihypertensive therapy with the combination of L/HCTZ in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension reaches a target BP faster in a higher proportion of patients, with fewer adverse events and less need for a third drug regimen than the conventional stepped-care approach.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440643      PMCID: PMC2649188          DOI: 10.1016/s0828-282x(07)70771-7

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  28 in total

Review 1.  Improving safety reporting from randomised trials.

Authors:  John P A Ioannidis; Joseph Lau
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  After the diagnosis: adherence and persistence with hypertension therapy.

Authors: 
Journal:  Am J Manag Care       Date:  2005-11       Impact factor: 2.229

3.  Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population.

Authors:  A Benetos; M Safar; A Rudnichi; H Smulyan; J L Richard; P Ducimetieère; L Guize
Journal:  Hypertension       Date:  1997-12       Impact factor: 10.190

4.  Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; M J Schwartz
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

5.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

6.  Distribution of blood pressure and hypertension in Canada and the United States.

Authors:  M R Joffres; P Hamet; D R MacLean; G J L'italien; G Fodor
Journal:  Am J Hypertens       Date:  2001-11       Impact factor: 2.689

7.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

Review 8.  Evaluation of antihypertensive therapy: discrepancies between office and ambulatory recorded blood pressure.

Authors:  B Waeber; B Rutschmann; J Nüssberger; H R Brunner
Journal:  J Hypertens Suppl       Date:  1991-12

9.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension.

Authors:  Yves Lacourcière; Luc Poirier
Journal:  Am J Hypertens       Date:  2003-12       Impact factor: 2.689

View more
  1 in total

1.  Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension.

Authors:  D H Zappe; B F Palmer; D A Calhoun; D Purkayastha; R Samuel; K A Jamerson
Journal:  J Hum Hypertens       Date:  2009-12-10       Impact factor: 3.012

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.